Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator initiated phase Ib study assessing motixafortide for patients suffering from acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections

Next Previous
Trial Profile

An investigator initiated phase Ib study assessing motixafortide for patients suffering from acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Motixafortide (Primary)
  • Indications Adult respiratory distress syndrome; COVID-19 respiratory infection
  • Focus Adverse reactions

Most Recent Events

  • 03 Dec 2020 New trial record
  • 18 Nov 2020 According to a BioLineRx media release, a preliminary analysis is planned after ten patients have completed the initial treatment period. Based on the preliminary evaluation, a decision to continue or not will be conducted by Dr. Maor, together with the Company.
  • 18 Nov 2020 According to a BioLineRx media release, this study will be conducted at Wolfson Medical Center in Holon, Israel, with Dr. Yasmin Maor, Head of the Infectious Disease Unit, as lead investigator. Results from the preliminary analysis is expected in the first half of next year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top